Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy

Metabolism: Clinical and Experimental

Volumn 51, Issue 10, 2002, Pages 1274-1278

  Luef, Gerhard ^a   Abraham, Irene ^a   Hoppichler, Friedrich ^a   Trinka, Eugen ^a   Unterberger, Iris ^a   Bauer, Gerhard ^a   Lechleitner, Monika ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALBUMIN; ANTICONVULSIVE AGENT; C PEPTIDE; CARBAMAZEPINE; CHOLESTEROL; FATTY ACID; FATTY ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMOTRIGINE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROINSULIN; TRIACYLGLYCEROL; VALPROIC ACID;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFECT; EPILEPSY; FEMALE; GENERALIZED EPILEPSY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; LONG TERM CARE; METABOLIC DISORDER; MONOTHERAPY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

EID: 0036796130     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.34708     Document Type: Article

References (43)

1. Isojarvi JL, Laatikainen TJ, Knip M, et al: Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39:579-584, 1996
2. Verrotti A, Basciani F, Morresi S, et al: Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 53:230-232, 1999
3. Easter D, O'Bryan-Tear CG, Verity C: Weight gain with valproate or carbamazepine - A reappraisal. Seizure 6:121-125, 1997
4. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1601, 1988
5. Isojarvi JI, Tauboll E, Pakarinen AJ, et al: Altered ovarian function and cardiovascular risk in valproate-treated women. Am J Med 111:290-292, 2001
6. Zhang Y, Proenca R, Maffei M, et al: Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994
7. Maffei M, Halaas J, Ravussin E, et al: Leptin levels in human and rodents: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1:1155-1161, 1995
8. Considine RV, Sinha MK, Heiman ML, et al: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295, 1996
9. Tatti P, Maselli L, Buonanno A, et al: Leptin levels in diabetic and nondiabetic subjects. Endocrine 15:305-308, 2001
10. Havel PJ: Control of energy homeostasis and insulin action by adipocyte hormones: Leptin, acylation stimulating protein and adiponectin. Curr Opin Lipidol 13:51-59, 2002
11. Seufert J, Kieffer TJ, Leech CA, et al: Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metabol 84:670-676, 1999
12. Cases JA, Gabriely I, Ma XH, et al: Physiological increase in plasma leptin inhibits insulin secretion in vivo. Diabetes 50:348-357, 2001
13. Wang J, Obici S, Morgan K, et al: Overfeeding rapidly induces leptin and insulin resistance. Diabetes 50:2786-2791, 2001
14. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
15. Hotamisligil GS, Peraldi P, Budavari A, et al: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Science 271:665-668, 1996
16. Kern PA, Ranganathan S, Li C, et al: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol 280:E745-757, 2001
17. MacGarry JD: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7-18, 2002
18. Boden G: Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians 111:241-248, 1999
19. Roden M, Krssak M, Stingl H, et al: Rapid impairment of skeletal muscle glucose transport/physphorylation by free fatty acids in humans. Diabetes 48:358-364, 1999
20. Grill V, Ovigstad E: Fatty acids and insulin secretion. Br J Nutr 1:79-84, 2000 (suppl)
21. Yoshikawa H, Tajiri Y, Sako Y, et al: Effects of free fatty acids on beta-cell functions: A possible involvement of peroxisome proliferator-activated receptors alpha or pancreatic/duodenal home box. Metabolism 50:613-618, 2001
22. Davis R, Peters DM, McTavish D: Valproic acid: A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332-372, 1994
23. Löscher W: Valproate: A reappraisal of its pharmacodynamic properties and mechanism of action. Prog Neurol 58:31-59, 1999
24. Johannessen CU: Mechanism of action of valproate: A commendatory. Neurochem Int 37:103-110, 2000
25. Vorum H, Gram L, Homore B: Valproate and palamitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Res 16:55-64, 1993
26. Patsch W, Brown SA, Morrisett J, et al: A dual precipitation method evaluated for measurement of cholesterol in high-density lipoprotein HDL2 and HDL3 in human plasma. Clin Chem 35:265-270, 1989
27. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
28. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28:412-419, 1985
29. Bonora E, Targher G, Alberiche M, et al: Homeostasis model assessment closely mirrors the glucose clamp in the assessment of insulin sensitivity. Diabetes Care 1:57-63, 2000
30. Sweeney G, Keen J, Somwar R, et al: High leptin levels acutely inhibit insulin-stimulated glucose uptake without affecting glucose transporter 4 translocation in 16 rat skeletal muscle cells. Endocrinology 142:4806-4812, 2001
31. Nisoli E, Carruba MO, Tonello C, et al: Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes 49:319-324, 2000
32. Ichiyama T, Okada K, Lipton JM, et al: Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappa B. Brain Res 857:246-257, 2000
33. Carpentier A, Mittelman SD, Bergman RN, et al: Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese non-diabetic humans but not in individuals with type 2 diabetes. Diabetes 49:399-408, 2000
34. Ahren B: Autonomic regulation of islet hormone secretion-implications for health and disease. Diabetologia 43:393-410, 2000
35. Satin LS, Kinard TA: Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: What messages do acetylcholine, glutamate, and GABA transmit? Endocrine 8:213-223, 1998
36. Glassmeier G, Hopfner M, Buhr H, et al: Expression of functional GABAA receptors in isolated human insulinoma cells. Ann N Y Acad Sci 859:241-248, 1998
37. Gomez R, Asnis N, Tannhauser SL, et al: GABA agonists differentially modify blood glucose levels of diabetic rats. Jpn J Pharmacol 80:327-331, 1999
38. Shi Y, Kanaani J, Menard-Rose V, et al: Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am J Physiol 279:E684-E694, 2000
39. Biton V, Mirza W, Montouris G, et al: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 56:172-177, 2001
40. Ratt YA, Vainionpaa L, Knip M, et al: The effects of valproate, carbamazepine, and oxcarbamazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 103:588-593, 1999
41. Hogan RE, Bertrand ME, Deaton RL, et al: Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res 41:23-28, 2000
42. Devinsky O, Vuong A, Hammer A, et al: Stable weight during lamotrigine therapy: A review of 32 studies. Neurology 54:973-975, 2000
43. Horlick MB, Rosenbaum M, Nicolson M, et al: Effect of puberty on the relationship between circulating leptin and body composition. J Clin Endocrinol Metab 85:2509-2515, 2000